Clinical Report: Systemic Immune-Inflammation Index in Coronary Heart Disease

Overview

The Systemic Immune-Inflammation Index (SII) integrates platelet, neutrophil, and lymphocyte counts to quantify thrombo-inflammatory burden in coronary heart disease (CHD). SII shows phenotype-dependent predictive utility, with high accuracy in acute coronary syndrome (ACS) and more limited use in chronic coronary syndrome (CCS).

Background

Coronary heart disease remains a leading cause of morbidity and mortality worldwide, driven by complex thrombo-inflammatory mechanisms involving platelets, neutrophils, and lymphocytes. Traditional inflammatory markers like CRP inadequately capture the multidimensional interactions underlying CHD pathophysiology. The SII, calculated as (platelets × neutrophils) / lymphocytes, offers a novel composite biomarker reflecting thrombosis, inflammation, and immunity simultaneously, facilitating improved risk stratification and clinical decision-making.

Data Highlights

Key Findings

• SII effectively captures the synergistic amplification of platelet-neutrophil interactions central to thromboinflammation in CHD.
• Its predictive value is highest in acute coronary syndrome, reflecting acute thromboinflammatory storms.
• In chronic coronary syndrome, SII serves primarily as a marker of background inflammation rather than a strong prognostic indicator.
• Clinical thresholds have been proposed for acute risk (>900–1400), complication stratification (450–650 screening; >1000 diagnosis), and chronic monitoring (>650).
• Significant heterogeneity exists in reported cut-off values (459–2174), limiting standardization.
• Comparisons with other composite indices like SIRI and PIV remain inconclusive, and most evidence derives from observational studies.

Clinical Implications

SII provides clinicians with a comprehensive biomarker that integrates thrombosis, inflammation, and immunity to improve risk stratification in CHD, especially in acute settings. Its use may guide early identification of patients at high risk for adverse events and microvascular complications, informing targeted interventions. However, standardized cut-offs and prospective validation are needed before routine clinical implementation.

Conclusion

The Systemic Immune-Inflammation Index represents a promising tool for capturing the complex thrombo-inflammatory processes in coronary heart disease, with particular strength in acute coronary syndrome risk prediction. Future research should focus on validating its mechanistic specificity and exploring its role in guiding precision therapies.

References

1. Hu et al. 2014 -- Introduction of SII in Oncology
2. Seo et al. 2018 -- Validation of SII in Cardiovascular Prognosis
3. CANTOS Study 2017 -- Anti-inflammatory Therapy in CHD
4. LoDoCo2 and COLCOT Trials -- Colchicine in Cardiovascular Disease